Morris M E, Pang K S
Faculty of Pharmacy, University of Toronto, Ontario, Canada.
J Pharmacokinet Biopharm. 1987 Oct;15(5):473-96. doi: 10.1007/BF01061758.
Modulating effects of competing pathways, exemplified by sulfation (high affinity-low capacity) and glucuronidation (low affinity-high capacity), on drug disappearance and metabolite formation were investigated in a simulation study. The phenomenon of substrate recruitment of hepatocyte activity in drug removal and metabolite formation was shown with respect to inlet substrate concentration, and drug processing from inlet to outlet by enzyme systems localized differentially along the sinusoidal flow path in liver. Three enzymic distribution models: (A) sulfation and glucuronidation evenly distributed in liver, (b) sulfation occurring exclusively in the first half of the liver and glucuronidation in the second half, and (C) glucuronidation solely in the first half and sulfation in the second half, were described. The influence of Km and Vmax of the competing pathway, including enzyme induction (increase in Vmax), on any given pathway was also explored. Competing pathways exert their effects on other given pathways by modulating intrahepatic drug concentration from the inlet to outlet of the liver. When a competing pathway is similarly distributed or is at an anterior location to another pathway, the former pathway effectively reduces intrahepatic drug concentrations which reach downstream hepatocytes for recruitment of activity. For example, when glucuronidation activity is anterior to sulfation activity (defined with respect to flow direction), sulfation is without an effect on glucuronidation, but glucuronidation exerts a maximal influence over sulfation rates (Model C). When glucuronidation is in direct competition with sulfation (Model A) or is posteriorly distributed to sulfation (Model B), saturation of the high-affinity sulfation pathway leads to greater fluxes of substrate available downstream for glucuronidation. This results in an apparent compensatory increase in glucuronidation with reduced sulfation capacity, which occurs at input concentrations greater than the Km for sulfation but less than the Km for glucuronidation. This compensation pattern is more prominent for highly extracted compounds where both sulfation and glucuronidation are effective pathways in drug removal, and where large intrahepatic drug concentration gradients are expected. Since the physiologic description of intrahepatic drug concentration is often described by a concentration gradient from the inlet to outlet of the liver, the logarithmic average concentration has been used to estimate the mean liver concentration in the determination of kinetic constants for enzymic reactions.(ABSTRACT TRUNCATED AT 400 WORDS)
在一项模拟研究中,考察了以硫酸化(高亲和力 - 低容量)和葡萄糖醛酸化(低亲和力 - 高容量)为代表的竞争途径对药物消除和代谢物形成的调节作用。研究显示了肝细胞活性在药物清除和代谢物形成过程中的底物募集现象,这与入口底物浓度有关,以及药物通过肝脏中沿正弦流路不同定位的酶系统从入口到出口的处理过程。描述了三种酶分布模型:(A)硫酸化和葡萄糖醛酸化在肝脏中均匀分布;(B)硫酸化仅发生在肝脏的前半部分,葡萄糖醛酸化发生在后半部分;(C)葡萄糖醛酸化仅在前半部分,硫酸化在后半部分。还探讨了竞争途径的Km和Vmax(包括酶诱导,即Vmax增加)对任何给定途径的影响。竞争途径通过调节肝脏入口到出口的肝内药物浓度对其他给定途径发挥作用。当一个竞争途径与另一个途径分布相似或位于其前方时,前一个途径有效地降低了到达下游肝细胞进行活性募集的肝内药物浓度。例如,当葡萄糖醛酸化活性相对于硫酸化活性位于前方(根据流动方向定义)时,硫酸化对葡萄糖醛酸化没有影响,但葡萄糖醛酸化对硫酸化速率有最大影响(模型C)。当葡萄糖醛酸化与硫酸化直接竞争时(模型A)或分布在硫酸化后方时(模型B),高亲和力硫酸化途径的饱和导致下游可用于葡萄糖醛酸化的底物通量增加。这导致在硫酸化能力降低的情况下葡萄糖醛酸化出现明显的代偿性增加,这种情况发生在输入浓度大于硫酸化的Km但小于葡萄糖醛酸化的Km时。对于高度摄取的化合物,这种补偿模式更为突出,在这些化合物中,硫酸化和葡萄糖醛酸化都是药物清除的有效途径,并且预计会有较大的肝内药物浓度梯度。由于肝内药物浓度的生理学描述通常用从肝脏入口到出口的浓度梯度来表示,因此在酶促反应动力学常数的测定中,对数平均浓度已被用于估计肝脏平均浓度。(摘要截断于400字)